PL4062916T3 - Leczenie pacjentów z chorobą Fabry’ego mających pewne mutacje - Google Patents

Leczenie pacjentów z chorobą Fabry’ego mających pewne mutacje

Info

Publication number
PL4062916T3
PL4062916T3 PL22165669.7T PL22165669T PL4062916T3 PL 4062916 T3 PL4062916 T3 PL 4062916T3 PL 22165669 T PL22165669 T PL 22165669T PL 4062916 T3 PL4062916 T3 PL 4062916T3
Authority
PL
Poland
Prior art keywords
certain mutations
fabry patients
treating fabry
treating
patients
Prior art date
Application number
PL22165669.7T
Other languages
English (en)
Inventor
Jeff Castelli
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65803261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4062916(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of PL4062916T3 publication Critical patent/PL4062916T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL22165669.7T 2017-05-30 2018-05-30 Leczenie pacjentów z chorobą Fabry’ego mających pewne mutacje PL4062916T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762512458P 2017-05-30 2017-05-30
US201862626953P 2018-02-06 2018-02-06

Publications (1)

Publication Number Publication Date
PL4062916T3 true PL4062916T3 (pl) 2025-03-17

Family

ID=65803261

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18733415.6T PL3630114T3 (pl) 2017-05-30 2018-05-30 Migalastat do leczenia pacjentów z chorobą Fabry'ego z zaburzeniem czynności nerek
PL22165669.7T PL4062916T3 (pl) 2017-05-30 2018-05-30 Leczenie pacjentów z chorobą Fabry’ego mających pewne mutacje

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL18733415.6T PL3630114T3 (pl) 2017-05-30 2018-05-30 Migalastat do leczenia pacjentów z chorobą Fabry'ego z zaburzeniem czynności nerek

Country Status (14)

Country Link
EP (9) EP4324522B1 (pl)
CN (4) CN120732857A (pl)
DK (2) DK4062916T3 (pl)
ES (3) ES3052647T3 (pl)
FI (2) FI3630114T3 (pl)
HR (2) HRP20241738T1 (pl)
HU (2) HUE069837T2 (pl)
LT (2) LT3630114T (pl)
PL (2) PL3630114T3 (pl)
PT (2) PT3630114T (pl)
RS (2) RS66376B1 (pl)
SI (2) SI4062916T1 (pl)
SM (2) SMT202500016T1 (pl)
TW (4) TWI775453B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3982962A1 (en) * 2019-06-11 2022-04-20 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having renal impairment
EP3895708A3 (en) * 2019-08-07 2022-01-19 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2024745B1 (en) * 2006-05-16 2015-07-08 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for fabry disease
CA2682441A1 (en) 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of fabry disease using pharmacological chaperones
CA2685332A1 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
PL2946785T3 (pl) 2008-02-12 2019-04-30 Amicus Therapeutics Inc Sposób przewidywania odpowiedzi na leczenie chorób farmakologicznymi białkami chaperonowymi
EP2683382B1 (en) * 2011-03-11 2020-04-22 Amicus Therapeutics, Inc. Dosing regimens for the treatment of fabry disease
US20120283290A1 (en) * 2011-05-06 2012-11-08 Amicus Therapeutics Inc. Quantitation of gl3 in urine
TW202408513A (zh) 2016-07-19 2024-03-01 美商阿米庫斯醫療股份有限公司 治療ert初治的和已經歷ert的患者中之法布瑞氏症
WO2019017938A1 (en) * 2017-07-19 2019-01-24 Amicus Therapeutics, Inc. TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES

Also Published As

Publication number Publication date
DK3630114T3 (da) 2024-01-29
ES3002433T3 (en) 2025-03-06
EP4324522B1 (en) 2025-12-10
EP4374918A2 (en) 2024-05-29
TW201900165A (zh) 2019-01-01
EP4324522A2 (en) 2024-02-21
EP4327869A2 (en) 2024-02-28
FI3630114T3 (fi) 2024-01-30
EP4062916B1 (en) 2024-10-09
PL3630114T3 (pl) 2024-03-25
LT4062916T (lt) 2025-01-10
TW202322814A (zh) 2023-06-16
EP4327869A3 (en) 2024-05-22
RS65230B1 (sr) 2024-03-29
EP4245366A2 (en) 2023-09-20
EP4374918A3 (en) 2024-08-14
EP4327868A2 (en) 2024-02-28
TWI775453B (zh) 2022-08-21
HRP20240061T1 (hr) 2024-03-29
ES3052647T3 (en) 2026-01-12
SI3630114T1 (sl) 2024-03-29
EP4062915A1 (en) 2022-09-28
CN119587544A (zh) 2025-03-11
RS66376B1 (sr) 2025-02-28
EP4245366A3 (en) 2023-11-29
FI4062916T3 (fi) 2025-01-10
DK4062916T3 (da) 2025-01-13
EP3630114A1 (en) 2020-04-08
CN120732857A (zh) 2025-10-03
SMT202400037T1 (it) 2024-03-13
PT3630114T (pt) 2024-02-01
ES2970419T3 (es) 2024-05-28
EP4324522A3 (en) 2024-05-22
TW202140000A (zh) 2021-11-01
EP3630114B1 (en) 2023-11-01
EP4245366A9 (en) 2023-12-06
EP4374918B1 (en) 2025-07-16
HRP20241738T1 (hr) 2025-02-28
HUE069837T2 (hu) 2025-04-28
SI4062916T1 (sl) 2025-04-30
LT3630114T (lt) 2024-02-12
CN111278438A (zh) 2020-06-12
EP4327869B1 (en) 2025-12-10
HUE065615T2 (hu) 2024-06-28
TWI894750B (zh) 2025-08-21
TWI795408B (zh) 2023-03-11
EP4635496A1 (en) 2025-10-22
EP4062916A1 (en) 2022-09-28
SMT202500016T1 (it) 2025-03-12
TW202440104A (zh) 2024-10-16
CN117357524A (zh) 2024-01-09
PT4062916T (pt) 2025-01-13

Similar Documents

Publication Publication Date Title
IL258002A (en) Cenicriviroc combination therapy for the treatment of fibrosis
GB201608885D0 (en) Treatment
ZA201807653B (en) New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions
ZA201705847B (en) Treatment of pain
GB201604658D0 (en) Treatment for pain
LT4062916T (lt) Tam tikras mutacijas turinčių fabri pacientų gydymas
EP3277726A4 (en) Pain treatment
GB201718985D0 (en) Treatment
GB201711677D0 (en) Combination treatment
GB201713650D0 (en) Treatment
GB201704949D0 (en) Combination treatment
GB201706955D0 (en) Treatment
GB201507717D0 (en) Treatment couch
GB201704043D0 (en) Coagulation Therapy
GB201505205D0 (en) Treatment for pain
GB201504688D0 (en) Treatment for pain
GB201617107D0 (en) Treatment
GB201612260D0 (en) Treatment
GB201612193D0 (en) Treatment
AU2015901216A0 (en) Pain treatment
AU2015901215A0 (en) Pain treatment
GB201506944D0 (en) Therapeutic treatment
GB201609683D0 (en) Treatment
AU2015902062A0 (en) New Therapeutic Treatment Combination